# Oncogenes: When the Switch Sticks

> Many cancers trace back to signalling proteins whose switch is stuck on. This lesson shows that a cancer gene is an altered copy of one of the cell's own genes, as the story of a chicken tumour virus first revealed, then sorts the ways a signalling switch can stick in the on position. It explains why some changes act through one altered copy of a gene while others need both copies lost, and why a tumour usually needs more than one change yet can come to depend on one of them. Afterwards you will be able to say why a drug aimed at one protein can sometimes shrink a tumour that carries many mutations.

Course: Cell Signaling (Evolution, disease and tools). Level: advanced university and graduate. About 16 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/oncogenes/

Builds on: GTPase Switches: The Timer · Protein Modules: SH2, SH3, PTB, PDZ and PH · Receptor Tyrosine Kinases

## What you'll learn

- Explain that an oncogene is an altered copy of a normal cell gene, using the Rous sarcoma virus and src story, and define proto-oncogene, oncogene and tumour suppressor.
- Sort five ways a signalling switch can stick on, with an example of each: Ras, Src, HER2, BCR-ABL, and the loss of PTEN, neurofibromin or APC.
- Explain why a gain of function acts when one copy of a gene is changed and why loss of an off-switch usually needs both copies gone.
- Explain why one stuck switch is seldom enough to make a tumour and why a tumour can come to depend on the one it has.

**A cancer gene is usually one of the cell’s own genes, altered so that a signalling switch sticks on.** Jam an on-step or lose an off-step in a pathway that tells a cell to divide, and the cell can start to divide on its own. This lesson sorts the ways that happens, shows why some changes act through one altered copy of a gene while others need both copies lost, and then asks why one stuck switch is seldom enough to make a tumour and why a tumour can still come to depend on the one it has. The first proof that a cancer gene is the cell’s own came from a chicken. In 1911 Peyton Rous passed a ground-up hen tumour through a filter that stops bacteria and injected the clear fluid into healthy hens. New tumours grew where the needle went in. Something smaller than a bacterium had carried the cancer from bird to bird. Sixty-five years later the gene this agent uses to cause cancer turned up somewhere surprising: in the DNA of healthy birds, as one of the birds’ own genes.

## The story: the cancer gene was the chicken’s own

**Film transcript: A Gene of the Birds Themselves**

### Film transcript: A Gene of the Birds Themselves

Where did a virus get a cancer gene? In San Francisco, Michael Bishop and Harold Varmus shared a laboratory. A French postdoctoral fellow there, Dominique Stehelin, made a radioactive strand of DNA. It matched the src gene and no other part of the virus. A single strand of DNA sticks to its matching sequence. So this probe could ask whether any sample of DNA held a relative of src. The probe stuck to DNA from chickens that had never met the virus. That alone proved little. A leading idea of the day held that old infections had left viral genes behind in chicken chromosomes. So a match in chickens could still be a leftover from an old infection.

So Stehelin tried duck, quail and emu. An emu is a flightless bird at a great evolutionary distance from the chicken. The probe stuck to all of them. The matches were close enough that Varmus judged the sequence had been conserved for at least a hundred million years. A sequence shared across that distance is older than any infection of chickens. It was a gene of the birds themselves. Later work found it in mammals, people included. The virus had picked up the cell's gene by accident. A normal gene that can become an oncogene when it is altered is a proto-oncogene. What the virus carries now is an altered copy.

The hen’s tumour was a sarcoma, a cancer of connective tissue. Before Rous trusted his filter he tested it against a bacterium, and it held the bacterium back. So the agent was smaller than a bacterium, the size of a virus, and that was all the filter could say. By Rous’s own account his result was doubted for about fifteen years.

The agent is now called Rous sarcoma virus. By the early 1970s Peter Vogt and others had isolated mutants of it that still multiplied but could no longer turn a normal cell into a tumour cell, and Peter Duesberg and his colleagues found that their RNA was missing a piece. The missing piece held a gene, named *src* (say “sark”) for sarcoma. A gene that can turn a cell cancerous is an **oncogene**.

Where did a virus get such a gene? In the laboratory that Michael Bishop and Harold Varmus shared in San Francisco, a French postdoctoral fellow, Dominique Stehelin, made a radioactive strand of DNA that matched *src* and no other part of the virus. A single strand of DNA sticks to its matching sequence, so this probe could ask whether any sample of DNA held a relative of *src*. It stuck to DNA from chickens that had never met the virus.

That alone proved little. A leading idea of the day held that old infections had left viral genes behind in chicken chromosomes. So Stehelin tried duck, quail and emu, a flightless bird at a great evolutionary distance from the chicken. The probe stuck to all of them, and the matches were close enough that Varmus judged the sequence had been conserved for at least 100 million years. A sequence shared across that distance is older than any infection of chickens. It was a gene of the birds themselves, and later work found it in mammals, people included.

A normal gene that can become an oncogene when it is altered is a **proto-oncogene**. The virus had picked up the cell’s gene, *c-src*, by accident, and what it carries now is an altered copy, *v-src*.

What does the gene make? The Src protein is a kinase that puts its phosphate on tyrosine, a story told in [the phosphorylation lesson](https://stemhop.com/lessons/phosphorylation-switch). And what has v-Src lost? [The lesson on interaction modules](https://stemhop.com/lessons/protein-interaction-modules) showed how c-Src holds itself shut: a tyrosine near its tail end (tyrosine 527 in the chicken protein) carries a phosphate, the protein’s own SH2 domain grips it, and the kinase is clamped. In v-Src the tail has been replaced and that tyrosine is gone. Nothing closes the clamp, so the kinase runs all the time, and a few changes elsewhere in the protein raise its activity further.

*Figure (AI-generated illustration).* c-Src is clamped shut when its own SH2 domain grips the phosphate on a tail tyrosine. In v-Src the tail has been replaced and that tyrosine is gone, so nothing closes the clamp and the kinase runs all the time. Image: two schematic Src proteins. In c-Src the SH2 domain grips a phosphate on the tail and clamps the kinase shut; in v-Src the tail is replaced, nothing is gripped, and the kinase is open and running.

## The idea: five ways to stick a switch

Every pathway in this course has an on-step and an off-step. Jam an on-step or remove an off-step, and a cell that should divide only when told can start to divide on its own, unless its checkpoints stop it. Many kinases have been linked to disease, and the ways a kinase or any other switch goes wrong fall into a short list.

| What changes | Example | Why the switch sticks | Pathway taught in |
| --- | --- | --- | --- |
| One amino acid, breaking the off-step | Ras G12V or Q61 | Ras hydrolyses its GTP only slowly, even with a GAP | [GTPase switches](https://stemhop.com/lessons/gtpase-switches), [Ras to MAPK](https://stemhop.com/lessons/ras-to-mapk) |
| The piece that holds a kinase shut is lost | v-Src | No tail tyrosine for the SH2 domain to grip | [Interaction modules](https://stemhop.com/lessons/protein-interaction-modules) |
| Too many copies of a normal gene | HER2 | HER2 needs no growth factor of its own, and crowded receptors pair unaided | [Receptor tyrosine kinases](https://stemhop.com/lessons/receptor-tyrosine-kinases) |
| Two genes joined | BCR-ABL | The BCR part holds ABL kinases together | [Receptor tyrosine kinases](https://stemhop.com/lessons/receptor-tyrosine-kinases), [the phosphorylation switch](https://stemhop.com/lessons/phosphorylation-switch) |
| The off-protein is lost | PTEN, neurofibromin, APC | PIP3, Ras-GTP or β-catenin is not cleared | [PI 3-kinase and Akt](https://stemhop.com/lessons/pi3k-akt-insulin), [GTPase switches](https://stemhop.com/lessons/gtpase-switches), [Wnt signalling](https://stemhop.com/lessons/wnt-signaling) |

Rows one and two you have met. In row three, roughly 15 to 20 percent of breast cancers have the HER2 gene copied many times over. The protein is normal, but there is far too much of it. HER2 has no growth factor of its own. Normally it pairs with a relative such as EGFR after that partner has bound its growth factor. With far too many HER2 receptors in the membrane, they pair with each other and with their partners unaided.

Row four is the join of two genes. In chronic myeloid leukaemia a piece of chromosome 22 is attached to chromosome 9, and the join fuses two genes, BCR and ABL. ABL makes a tyrosine kinase related to Src. The BCR part makes the fusion proteins stick to each other, so their kinase domains sit side by side and switch each other on, as paired receptors do.

*Figure (AI-generated illustration).* The join of two genes makes a fusion protein. The BCR part makes the fusion proteins stick to each other, so their ABL kinase domains sit side by side and switch each other on, as paired receptors do. Image: one continuous BCR–ABL fusion protein contains a BCR-derived part and an ABL kinase domain. A schematic pair associates through its BCR parts, bringing the ABL kinase domains together; arrows from each kinase to the other show activation by phosphorylation.

“Gain of function mutations in RTKs” could head a table of its own: EGFR and its relatives, KIT, MET and RET are each found stuck on in particular human tumours.

Row five is different in kind. Phosphatase and tensin homolog (PTEN) removes the phosphate that PI 3-kinase adds to make phosphatidylinositol 3,4,5-trisphosphate (PIP3), neurofibromin is a GAP for Ras, and APC is part of the complex that marks β-catenin for destruction. No on-step is jammed here. An off-step is missing. A gene whose loss lets cells grow when they should not is a **tumour suppressor**.

## One copy or two: gain acts alone, loss needs both

You carry two copies of nearly every gene, one from each parent. For the first four rows a change at one copy is usually enough. The altered protein, or the extra protein made from an amplified gene, signals without being told to, and the normal protein from the other copy does not switch it off. This is a gain of function, and it is dominant: it shows even when the other copy is normal.

For row five, one good copy usually makes enough protein to do the job, so both copies must go before the off-step fails. Alfred Knudson reached this idea in 1971 from the ages at which children were diagnosed with retinoblastoma, a tumour of the eye. The inherited form, often in both eyes, appeared on a schedule that fitted one chance event, and the form that is not inherited fitted two. He proposed that the tumour takes two “hits”, and that children with the inherited form are born with the first in every cell. The two hits turned out to be the two copies of one gene.

*Interactive on the lesson page:* One hit or two: when does the switch stick?

There are many ways to break a protein and few ways to jam it on. That is why Ras changes in tumours cluster at positions 12, 13 and 61, while changes in a tumour suppressor are scattered along the gene. There are exceptions to both rules, set out under Going deeper at the end of the lesson.

## Why one stuck switch is not enough

A normal cell treats a growth signal that never stops as a fault. In 1983 Robert Weinberg’s laboratory put an always-on *ras* gene into cells taken fresh from rat embryos. The cells did not become tumour cells. Nor did they with *myc* alone, a gene for a transcription factor that drives growth. With both genes together they did.

What stops a cell with one stuck switch? Checkpoints do. In normal cells p53, from [the stress lesson](https://stemhop.com/lessons/stress-signals), answers excess growth signalling much as it answers damaged DNA, and it halts the cell or kills it. A cell that gets past p53 still needs the survival signals of [the cell death lesson](https://stemhop.com/lessons/death-receptors-bcl2-caspases), or it dies by apoptosis. So a tumour collects changes: a stuck on-switch, a lost off-switch, a broken checkpoint, a block on death. In the colon a common order is known, with loss of APC early, an always-on Ras later and loss of p53 later still.

## A tumour that needs its oncogene

How can we exploit this to treat cancer? A cell with several changes sounds like a cell with no single weak point. The surprise is that many tumours stay dependent on one of their stuck switches. In mice built so that an oncogene can be turned off at will, tumours that grew with the oncogene on have shrunk when it was turned off. The other mutations were still there, yet the cells stopped dividing or died. This is why a drug aimed at one protein can sometimes shrink a tumour that carries many mutations. Imatinib against BCR-ABL, from the biochemistry course, is the best-known case. The next lesson is about those drugs.

The dependence is called oncogene addiction, and its cause is still debated. One idea uses the negative feedback of [the circuits lesson](https://stemhop.com/lessons/signaling-circuits): a pathway stuck on keeps its own feedback inhibitors high, and those inhibitors may quiet the routes beside it, so that nothing is ready to take over when the stuck signal is removed. Another idea is that survival signals fade faster than death signals once the oncogene is switched off. The ideas are not exclusive, and which one matters may differ from tumour to tumour.

### Design problem

Take the chain receptor, Ras, Raf, MAPK/ERK kinase (MEK), extracellular signal-regulated kinase (ERK), with an off-switch at each step. List every kind of single change you can think of that would leave ERK on with no growth factor present. Sort your list into changes that work when one copy of a gene is altered and changes that need both copies lost. Then say which kind you would expect to find more often as an inherited risk for cancer, and why.

> **One way to do it.** **One altered copy is enough (gain).** A receptor that pairs without growth factor, because of a point mutation, a missing outer part, too many copies, or fusion to a partner that pairs it. A Ras that a GAP cannot turn off. A Raf or a MEK fixed in its active shape (BRAF V600E, common in melanoma, is one).
>
> **Both copies usually must be lost (loss).** The GAP for Ras, neurofibromin. The phosphatases that strip phosphate from the receptor, MEK or ERK. The ligase that tags an active receptor for removal.
>
> **Inherited risk.** Expect the loss kind more often. An inherited change is in every cell from the first division. A strongly stuck on-switch in every cell disturbs the embryo, and the milder inherited activating changes in this pathway cause developmental syndromes called RASopathies. One lost copy of an off-switch is mostly silent while the second copy works, so most such people are born without tumours. Every cell is then one hit away from having no off-switch, and in a body of many billions of cells a second hit somewhere becomes likely. Neurofibromatosis type 1, one inherited bad copy of the neurofibromin gene, works this way. There are exceptions: inherited activating changes in the receptor RET cause a cancer syndrome.

## Going deeper

### How src was found, with names and dates

The 1976 hybridisation paper appeared in *Nature* in March 1976 under four names: Stehelin, Varmus, Bishop and Vogt. That Src is a kinase was reported in 1978 by two groups, Marc Collett and Ray Erikson, and Art Levinson with colleagues in the Bishop and Varmus laboratory. Two years later Tony Hunter and Bart Sefton showed that it puts its phosphate on tyrosine.

### How the BCR-ABL join was found

A small chromosome was seen in 1960 by Peter Nowell and David Hungerford in the blood cells of people with chronic myeloid leukaemia. In 1973 Janet Rowley showed that the missing piece of this chromosome 22 was attached to chromosome 9. Later work tied this join to the fusion of BCR and ABL.

### Exceptions to the one-copy rules

The normal copy is not always irrelevant: in mice, normal Kras restrains tumours driven by mutant Kras, and such tumours often lose the normal copy later. A broken protein can also act through one copy if it gets in the way: the laboratory tool Ras S17N stays in its GDP form and, by one model, ties up the exchange factor that normal Ras needs.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/oncogenes/
